Safety and immunogenicity of the malaria vaccine candidate MSP3 long synthetic peptide in 12-24 months-old Burkinabe children.
Sirima SB, Tiono AB, Ouédraogo A, Diarra A, Ouédraogo AL, Yaro JB, Ouédraogo E, Gansané A, Bougouma EC, Konaté AT, Kaboré Y, Traoré A, Chilengi R, Soulama I, Luty AJ, Druilhe P, Cousens S, Nébié I.
Sirima SB, et al. Among authors: ouedraogo e, ouedraogo al, ouedraogo a.
PLoS One. 2009 Oct 26;4(10):e7549. doi: 10.1371/journal.pone.0007549.
PLoS One. 2009.
PMID: 19855847
Free PMC article.
Clinical Trial.